U.S. FDA Approves Yescarta for Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic Therapy

SANTA MONICA, Calif.--(BUSINESS WIRE)--Mar. 5, 2021-- Kite, a Gilead Company (Nasdaq: GILD), today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to Yescarta® (axicabtagene...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news